Netherlands· NL-84e8dccb74a8
SOTYKTU 6 mg filmomhulde tabletten
A deucravacitinib product containing deucravacitinib, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Deucravacitinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AF07 (deucravacitinib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Deucravacitinib · ATC L04AF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of deucravacitinib costs, country by country.
Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deucravacitinib · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- FR France$22.97
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- DEUCRAVACITINIB
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Netherlands (NL)
- ATC code
- L04AF07
- ATC class
- Deucravacitinib
- Defined daily dose
- 6 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1718
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Deucravacitinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOTYKTUBristol-Myers Squibb Pharma EEIG, Dublin
- United StatesSOTYKTUE.R. Squibb & Sons, L.L.C.
- FinlandSOTYKTUBristol-Myers Squibb Pharma EEIG
- FranceSOTYKTU 6 mg, comprimé pelliculéBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- BelgiumSotyktu 6 mgBristol-Myers Squibb Pharma
- IcelandSOTYKTUBristol-Myers Squibb Pharma EEIG*
- NorwaySotyktuBristol-Myers Squibb Pharma EEIG
- PolandSotyktuBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sotyktu
- Liechtenstein · Sotyktu
- Norway · Sotyktu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f6297bca-7ca8-4b11-b815-2f724dd04f5c GET /v1/drugs/f6297bca-7ca8-4b11-b815-2f724dd04f5c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/sotyktu-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Deucravacitinib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129077",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROMELLOSEACETAATSUCCINAAT",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 0-WATER",
"MACROGOL 4000",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL (E 1203)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"DEUCRAVACITINIB"
],
"leaflet_url": null,
"authorised_at": "2023/03/24",
"procedure_number": "EMEA/H/C/005755",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1718",
"additional_monitoring": "Y"
}See everything about deucravacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.